Back to Newsroom

Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada

Toronto, Canada and Lausanne, Switzerland – September 30, 2014 – Trelstar® (triptorelin pamoate), indicated in Canada for the palliative treatment of hormone dependent advanced prostate cancer, is now available in a six-month dosing option (22.5 mg). The new dosing option eases the burden on patients, with a decreased number of injections and a low incidence of injection site pain, while providing long-term sustained testosterone suppression.

The announcement comes out of Actavis Specialty Pharmaceuticals Co. and Debiopharm Group™, the original developer and sole manufacturer of Trelstar®. Trelstar® was previously marketed by Paladin in Canada, and is currently marketed by Actavis Specialty Pharmaceuticals Co. as of July 1st, 2014.

Click here to read more